Patents by Inventor Andrew George Popplewell

Andrew George Popplewell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nucleic acid molecules encoding neutralising antibodies having specificity for human IL-17
    Patent number: 8329431
    Abstract: The invention relates to an antibody molecule having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecule and methods for producing said antibody molecule.
    Type: Grant
    Filed: August 26, 2011
    Date of Patent: December 11, 2012
    Assignee: UCB Pharma S.A.
    Inventors: Ralph Adams, Andrew George Popplewell, Stephen Edward Rapecki, Simon Peter Tickle
  • BIOLOGICAL PRODUCTS
    Publication number: 20120302739
    Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the clains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22.
    Type: Application
    Filed: July 13, 2012
    Publication date: November 29, 2012
    Inventors: ANDREW GEORGE POPPLEWELL, SIMON PETER TICKLE, HEATHER MARGARET LADYMAN
  • Antibody molecules which bind IL-17A and IL-17F
    Patent number: 8303953
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Grant
    Filed: October 18, 2007
    Date of Patent: November 6, 2012
    Assignee: UCB Pharma S.A.
    Inventors: Ralph Adams, Andrew George Popplewell, Stephen Edward Rapecki
  • Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereof
    Patent number: 8293237
    Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.
    Type: Grant
    Filed: March 21, 2008
    Date of Patent: October 23, 2012
    Assignees: UCB Pharma, S.A., Biogen Idec MA Inc.
    Inventors: Linda C. Burkly, Janine L. Ferrant-Orgettas, Ellen A. Garber, Yen-Ming Hsu, Lihe Su, Frederick R. Taylor, Ralph Adams, Derek Thomas Brown, Andrew George Popplewell, Martyn Kim Robinson, Anthony Shock, Kerry Louise Tyson
  • CALICHEAMICIN DERIVATIVE-CARRIER CONJUGATES
    Publication number: 20120213804
    Abstract: Methods for preparing monomeric cytotoxic drug/carrier conjugates with a drug loading significantly higher than in previously reported procedures and with decreased aggregation and low conjugate fraction (LCF) are described. Cytotoxic drug derivative/antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described. Monomeric calicheamicin derivative/anti-CD22 antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described.
    Type: Application
    Filed: February 13, 2012
    Publication date: August 23, 2012
    Applicant: WYETH HOLDINGS CORPORATION
    Inventors: ARTHUR KUNZ, Justin Keith Moran, Joseph Thomas Rubino, Neera Jain, Eugene Joseph Vidunas, John McLean Simpson, Paul David Robbins, Nishith Merchant, John Francis Dijoseph, Mark Edward Ruppen, Nitin Krishnaji Damle, Andrew George Popplewell
  • Neutralising antibody molecules having specificity for human IL-17
    Patent number: 8231875
    Abstract: The invention relates to an antibody molecule having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecule and methods for producing said antibody molecule.
    Type: Grant
    Filed: November 16, 2005
    Date of Patent: July 31, 2012
    Assignee: UCB Pharma S.A.
    Inventors: Ralph Adams, Andrew George Popplewell, Stephen Edward Rapecki, Simon Peter Tickle
  • ANTIBODY MOLECULES HAVING SPECIFICITY FOR HUMAN IL-6
    Publication number: 20120183996
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of IL-6, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Application
    Filed: November 3, 2011
    Publication date: July 19, 2012
    Inventors: RICHARD EVAN GELINAS, MITRA CHOUDHURY SINGHAL, YI ZHANG, ANDREW GEORGE POPPLEWELL, RALPH ADAMS
  • Antibody Molecules Which Bind Human IL-17
    Publication number: 20120129219
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecules and methods of producing the antibody molecules.
    Type: Application
    Filed: September 23, 2011
    Publication date: May 24, 2012
    Applicant: UCB PHARMA S.A.
    Inventors: Stephen Edward Rapecki, Andrew George Popplewell, Ralph Adams
  • Calicheamicin derivative-carrier conjugates
    Patent number: 8153768
    Abstract: Methods for preparing monomeric cytotoxic drug/carrier conjugates with a drug loading significantly higher than in previously reported procedures and with decreased aggregation and low conjugate fraction (LCF) are described. Cytotoxic drug derivative/antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described. Monomeric calicheamicin derivative/anti-CD22 antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described.
    Type: Grant
    Filed: May 2, 2003
    Date of Patent: April 10, 2012
    Assignee: Wyeth Holdings Corporation
    Inventors: Arthur Kunz, Justin Keith Moran, Joseph Thomas Rubino, Neera Jain, Eugene Joseph Vidunas, John McLean Simpson, Paul David Robbins, Nishith Merchant, John Francis DiJoseph, Mark Edward Ruppen, Nitin Krishnaji Damle, Andrew George Popplewell
  • Neutralising Antibody Molecules Having Specificity for Human IL-17
    Publication number: 20120034656
    Abstract: The invention relates to an antibody molecule having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecule and methods for producing said antibody molecule.
    Type: Application
    Filed: August 26, 2011
    Publication date: February 9, 2012
    Applicant: UCB PHARMA S.A.
    Inventors: Ralph Adams, Andrew George Popplewell, Stephen Edward Rapecki, Simon Peter Tickle
  • Antibody molecules having specificity for human IL-6
    Patent number: 8075889
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of IL-6, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Grant
    Filed: December 8, 2006
    Date of Patent: December 13, 2011
    Assignee: UCB Pharma S.A.
    Inventors: Richard Evan Gelinas, Mitra Choudhury Singhal, Yi Zhang, Andrew George Popplewell, Ralph Adams
  • Antibody molecules which bind to human IL-17
    Patent number: 8057794
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Grant
    Filed: June 25, 2007
    Date of Patent: November 15, 2011
    Assignee: UCB Pharma S.A.
    Inventors: Stephen Edward Rapecki, Andrew George Popplewell, Ralph Adams
  • Antibody molecules specific to human tumour necrosis factor alpha
    Patent number: 7977464
    Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNF?. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by TNF?.
    Type: Grant
    Filed: June 18, 2008
    Date of Patent: July 12, 2011
    Assignee: UCB Pharma S.A.
    Inventors: Diljeet Singh Athwal, Derek Thomas Brown, Andrew Neil Charles Weir, Andrew George Popplewell, Andrew Paul Chapman, David John King
  • BIOLOGICAL PRODUCTS
    Publication number: 20110165659
    Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the claims of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22.
    Type: Application
    Filed: March 16, 2011
    Publication date: July 7, 2011
    Inventors: ANDREW GEORGE POPPLEWELL, SIMON PETER TICKLE, HEATHER MARGARET LADYMAN
  • Biological products
    Patent number: 7919606
    Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22.
    Type: Grant
    Filed: September 23, 2008
    Date of Patent: April 5, 2011
    Assignee: UCB Pharma S.A.
    Inventors: Andrew George Popplewell, Simon Peter Tickle, Heather Margaret Ladyman
  • Biological products
    Patent number: 7842787
    Abstract: There are disclosed antibody molecules containing at least on CDR derived from a mouse monoclonal antibody having specificity for human KDR. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases in which VEGF and/or KDR are implicated.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: November 30, 2010
    Assignee: UCB Pharma S.A.
    Inventors: Andrew George Popplewell, Simon Peter Tickle, Karen Zinkewich-Peotti, Robert Kendall Morrison
  • Antibody Molecules Which Bind IL-17A and IL-17F
    Publication number: 20100266609
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Application
    Filed: October 18, 2007
    Publication date: October 21, 2010
    Applicant: UCB PHARMA S.A.
    Inventors: Ralph Adams, Andrew George Popplewell, Stephen Edward Rapecki
  • ANTIBODY MOLECULES HAVING SPECIFICITY FOR HUMAN OX40
    Publication number: 20100254978
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Application
    Filed: February 17, 2010
    Publication date: October 7, 2010
    Inventors: Alastair David Griffiths Lawson, Andrew Malcolm Nesbitt, Andrew George Popplewell, Stevan Graham Shaw, Diana Shpektor, Yi Zhang
  • Antibody Molecules Having Specificity for Human IL-1B
    Publication number: 20100158913
    Abstract: The invention relates to an antibody molecule having specificity for antigenic determinants of IL-1?, therapeutic uses of the antibody molecule and methods for producing said antibody molecule.
    Type: Application
    Filed: September 29, 2009
    Publication date: June 24, 2010
    Applicant: UCB PHARMA, S.A.
    Inventors: Alastair David Griffiths Lawson, Andrew George Popplewell
  • BINDING PROTEINS, INCLUDING ANTIBODIES, ANTIBODY DERIVATIVES AND ANTIBODY FRAGMENTS, THAT SPECIFICALLY BIND CD154 AND USES THEREOF
    Publication number: 20100104573
    Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.
    Type: Application
    Filed: March 21, 2008
    Publication date: April 29, 2010
    Applicants: UCB Parma S.A., Biogen Idec MA, Inc.
    Inventors: Linda C. Burkly, Janine L. Ferrant-Orgettas, Ellen A. Garber, Yen-Ming Hsu, Lihe Su, Frederick R. Taylor, Ralph Adams, Derek Thomas Brown, Andrew George Popplewell, Martyn Kim Robinson, Anthony Shock, Kerry Louise Tyson